Benzinga··Vandana SinghAstraZeneca's Rare Disease Drug Cuts Calcium Supplement Dependency by Over 5x
AstraZeneca's eneboparatide met Phase 3 endpoints for hypoparathyroidism, with 31.1% of patients achieving calcium independence versus 5.9% on placebo.
BMYCELGrAZNMBXrare diseasePhase 3 trial